Ovarian cancer is among the most lethal gynecologic malignancies, often diagnosed at advanced stages due to a lack of effective screening tools. Recent studies suggest that the platelet-to-lymphocyte ratio (PLR), an indicator of systemic inflammation, may serve as a potential biomarker for diagnosing and staging ovarian cancer. We conducted a systematic review and meta-analysis, adhering to PRISMA guidelines. We searched the PubMed/Medline, Scopus, Web of Science, and EMBASE databases. We pooled data using a random-effects model to assess the sensitivity, specificity, and diagnostic performance of PLR in ovarian cancer. The meta-analysis of 22 studies comprising 5740 participants showed significantly elevated platelet-to-lymphocyte ratio (PLR) values in ovarian cancer patients compared to healthy controls, with a mean difference of 46.84 ( < 0.001). Additionally, PLR demonstrated utility in distinguishing benign from malignant lesions and early-stage from advanced-stage ovarian cancer. While PLR shows potential as a cost-effective and accessible biomarker for ovarian cancer diagnosis and staging, its diagnostic accuracy remains moderate. Therefore, combining PLR with other diagnostic tools enhances clinical decision-making.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3390/ijms26051841 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mapping the landscape of vitamin D in cancer studies: a systematic global investigation.
J Diabetes Metab Disord
June 2025
Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular - Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Purpose: This comprehensive study examines the multifaceted relationship between vitamin D and cancer, synthesizing key scientific advancements and global research trends to guide future investigations and address critical gaps in the field.
Methods: Publications on vitamin D and cancer were retrieved from Scopus up to November 2024. English-language original and review articles were analyzed using Excel, VOSviewer, and Scimago Graphica, focusing on publication trends, citation impacts, and research themes.
Composite score of PD-1 CD8 tumor-infiltrating lymphocytes and CD57 CD8 tumor ascites lymphocytes is associated with prognosis and tumor immune microenvironment of patients with advanced high-grade serous ovarian cancer.
Chin J Cancer Res
January 2025
Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China.
Objective: The expression of programmed death 1 (PD-1) on CD8 T cells is associated with their activation and exhaustion, while CD57 serves as a senescence marker. The impact of PD-1 and CD57CD8 T cells on the prognosis of patients with advanced high-grade serous ovarian cancer (HGSOC) remain unclear.
Methods: We assessed the percentages of PD-1 and CD57CD8 T cells in tumor-infiltrating lymphocytes (TILs, n=85) and tumor ascites lymphocytes (TALs, n=87) using flow cytometry.
Small molecule inhibition of ubiquitin C-terminal hydrolase L1 alters cell metabolism proteins and exerts anti- or pro-tumorigenic effects contingent upon chemosensitivity status in high grade serous ovarian cancer.
Front Pharmacol
February 2025
Program in Women's Oncology, Women and Infants Hospital, Providence, RI, United States.
High grade serous ovarian cancer (HGSOC) is the most lethal of all gynecologic malignancies in which the majority of patients eventually develop chemoresistant recurrent disease. Ubiquitin C-terminal hydrolase L1 (UCHL1) is a deubiquitinating enzyme canonically known for its involvement in neurodegeneration, but recently has been shown to play a key role in tumorigenesis. Furthermore, UCHL1 has garnered attention across a multitude of cancer subtypes as it has the ability to be targeted through small molecule inhibition.
View Article and Find Full Text PDFOvarian cancer and isolated cardiophrenic lymph nodes metastases: a systematic review.
J Turk Ger Gynecol Assoc
March 2025
Metaxa Memorial Cancer Hospital, Piraeus, Greece.
Currently, there is limited information available on the best course of action for advanced epithelial ovarian cancer (OC) with isolated extra-peritoneal disease in the cardiophrenic lymph nodes. Recently, there have been numerous reports of successful surgical removal of metastatic cardiophrenic lymph nodes in patients with OC, mostly during primary or interval cytoreduction procedures. However, the optimal management of isolated, extra-peritoneal cardiophrenic lymph node metastasis (ICLNM) remains unclear, since this clinical scenario is rather uncommon in OC and chemotherapy is so far the indicated treatment for patients with from advanced stage disease.
View Article and Find Full Text PDFPrevalence of breast cancer in ovarian cancer patients and its impact on patient survival: An analysis of the surveillance, epidemiology, and end results data.
Tumori
March 2025
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Background: Patients with high-grade serous ovarian carcinoma (HGSOC) often have a personal and/or family history of breast cancers. However, the clinical association and underlying molecular interaction between breast cancer and HGSOC is not well understood. In this study, the clinical characteristics and outcomes of HGSOC patients with or without breast cancer were compared.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!